DK2185192T3 - Lentivirale genoverførselsvektorer og deres medicinske anvendelser - Google Patents

Lentivirale genoverførselsvektorer og deres medicinske anvendelser Download PDF

Info

Publication number
DK2185192T3
DK2185192T3 DK08827144.0T DK08827144T DK2185192T3 DK 2185192 T3 DK2185192 T3 DK 2185192T3 DK 08827144 T DK08827144 T DK 08827144T DK 2185192 T3 DK2185192 T3 DK 2185192T3
Authority
DK
Denmark
Prior art keywords
vsv
compounds
gag
protein
combination
Prior art date
Application number
DK08827144.0T
Other languages
English (en)
Inventor
Pierre Charneau
Anne-Sophie Beignon
Fréderic Philippe Coutant
Karine Courbeyrette
Original Assignee
Pasteur Institut
Theravectys
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07290980.7A external-priority patent/EP2020444B1/en
Priority claimed from EP07291251.2A external-priority patent/EP2047861B1/en
Application filed by Pasteur Institut, Theravectys, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK2185192T3 publication Critical patent/DK2185192T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (41)

1. Kombination af forbindelser til anvendelse til terapeutisk eller profylaktisk behandling af en infektion med et immundefektvirus, hvor forbindelserne administreres sekventielt til en mammaliavært til fremkaldelse af et beskyttende specifikt cellulært immunrespons mod infektionen, som mindst omfatter: (i) lentivirale vektorpartikler, der er pseudotypet med et første bestemt glycosyleret (G) protein fra et vesikulært stomatitisvirus (VSV); (ii) lentivirale vektorpartikler, der er pseudotypet med et andet bestemt VSV-G-protein, der er forskelligt fra det første bestemte VSV-G-protein; hvor den lentivirale vektorpartikel ifølge (i) og (ii) i dens genom omfatter et rekombinant polynukleotid, der koder for et eller adskillige polypeptider, der mindst omfatter ét antigen, der er afledt af et GAG-antigen fra immundefektvirusset og; hvor det første og andet VSV-G-protein er henholdsvis VSV-G fra Indiana-stammen og VSV-G fra New Jerseystammen, og eventuelt: (iii) lentivirale vektorpartikler, der er pseudotypet med et tredje bestemt VSV-G-protein, hvor det tredje VSV-G-protein ikke seroneutraliserer med det første og andet VSV-G-protein.
2. Kombination af forbindelser til anvendelse ifølge krav 1, hvor det rekombinante polynukleotid i genomet i vektorpartiklen ikke koder for et biologisk aktivt POL-polyprotein.
3. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 eller 2, hvor det første og andet og, hvis det er til stede, det tredje VSV-G-protein stammer fra vira med forskellige serotyper og især er valgt blandt VSV-G-proteiner, der udtrykkes af plasmiderne, der er deponeret ved CNCM som pThV-VSV.G (IND-CO) CNCM i-3842 eller som en alternativ version af pThV-VSV.G (IND-CO), CNCM i-4056, pThV-VSV.G (NJ-CO) CNCM i-3843 eller som en alternativ version pThV-VSV.G (NJ-CO) CNCM I-4058 eller pThV-VSV.G (COCAL-CO) CNCM i-4055, pThV-VSV.G (ISFA-CO) CNCM i-4057 og pThV-VSV.G (SVCV-CO) CNCM i-4059.
4. Kombination af forbindelser til anvendelse ifølge krav 1 eller 2, hvor mindst ét af det første og andet VSV-G-protein er rekombinant, og det/de rekombinant(e) VSV-G-protein(er) omfatter eksportdeterminanten YTDIE af VSV-G fra en Indiana-serotypestamme, og hvor det tredje VSV-G-protein, hvis det er til stede, er rekombinant, og det rekombinante VSV-G-protein omfatter eksportdeterminanten YTDIE af VSV-G fra en Indiana-serotypestamme.
5. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor en eller adskillige lentivirale vektorer er pseudotypet med VSV-G-protein(er), der er muteret, især ved substitution, tilføjelse eller deletion af en eller adskillige aminosyrerester i forhold til en eller flere bestemte native reference-VSV-G-proteiner eller er modificeret til forøgelse af dets glycosylering eller til forøgelse af dets ekspressionskapacitet eller dets optagelseskapacitet af de lentivirale partikler.
6. Kombination af forbindelser til anvendelse ifølge krav 5, hvor mutationen af VSV-G-proteinet påvirker en eller adskillige aminosyrerester af det transmembrane domæne af VSV-G.
7. Kombination af forbindelser ifølge et hvilket som helst af kravene 1 til 6, hvor det første og andet VSV-G-protein er forskellige og kodes af et nukleinsyremolekyle, der er indbefattet i plasmid pThV-VSV-G (IND-co), der er deponeret under nummer I-3842, eller en variant deraf, der er deponeret under nummer I-4056, eller i plasmid pThV-VSV-G (NJ-co), der er deponeret under nummer I-3843, eller en variant deraf, der er deponeret under nummer I-4058.
8. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor det første eller andet VSV-G-protein kodes af nukleinsyremolekylet, der omfatter sekvensen i figur 6 eller 7, eller hvor det første og andet kappeprotein er forskellige og har en aminosyresekvens valgt blandt de, der er vist i figur 6 eller 7.
9. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor det tredje eller det/de yderligere VSV-G-protein(er) er valgt blandt proteinet/proteinerne, der kodes af et nukleinsyremolekyle eller har en aminosyresekvens, der er vist i figur 6 til 13 eller 14 til 18.
10. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor den pseudotypede lentivirale vektor er en human lentivi rusbaseret vektor.
11. Kombination af forbindelser til anvendelse ifølge krav 10, hvor den pseudotypede lentivirale vektor er en HIV-baseret vektor.
12. Kombination af forbindelser til anvendelse ifølge krav 6 eller 7, hvor de pseudotypede lentivirale vektorpartikler er replikations-inkompetente lentivirale vektorer.
13. Kombination af forbindelser til anvendelse ifølge krav 7 eller 8, hvor de pseudotypede lentivirale vektorpartikler er integrerings-inkompetente lentivirale vektorer.
14. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor det lentivirale vektorgenom omfatter en funktionel lentiviral DNA-flap af HIV-1.
15. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 10 til 14, hvor: - 3’-LTR-sekvensen af det lentivirale vektorgenom mindst mangler aktivatoren (enhanceren) for U3-regionen, især hvor 3'-LTR mangler U3-regionen eller har en deletion af en del af U3-regionen; og/eller - U3-regionen af LTR-5' er erstattet af ikke-lentiviral U3 eller af en promotor, der er egnet til at drive tat-uafhængig primær transkription.
16. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor det lentivirale vektorgenom omfatter følgende sekvenser: 1. en 5'-LTR, eventuelt hvor den tat-afhængige U3-sekvens, der driver transkriptionen af genomet, er erstattet af en promotorsekvens; 2. et psi (qj)-indkapslingssignal; 3. en RRE (Rev-responsivt element)-sekvens; 4. en DNA-flapsekvens, der er indsat opstrøms for antigenet og fortrinsvis placeret i en omtrent central position i vektorgenomet; hvor antigenet er under kontrol af en promotor, især en cytomegalovirus (CMV)-promotor; 5. eventuelt en WPRE (skovmurmeldyr (Woodchuck)-hepatitis B-virus-post-responsivt element)-sekvens; og 6. en 3'-LTR-region, der mangler U3-regionen.
17. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor den lentivirale genomvektor i de lentivirale vektorpartikler er afledt af plasmid pTRIPAU3.CMV-GFP, der er deponeret ved CNCM under nummer i-2330 den 11. oktober 1999, eller af pTRIPAU3.CMV-SIV-GAGco-WPRE, der er deponeret ved CNCM under nummer 1-3841 den 10. oktober 2007, eller af pTRIPAU3.CMV-SIV-GAG-WPRE, der er deponeret ved CNCM under nummer i-3840 den 10. oktober 2007, ved substitution af GFP eller af den SIV-GAG-kodende sekvens med et HIV-GAG-afledt antigen.
18. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 17, hvor polynukleotidet koder for et antigen afledt af et GAG-antigen fra Hl V-1.
19. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 17, hvor polynukleotidet koder for et antigen afledt af GAG fra et immundefektvirus og har aminosyresekvensen for de naturlige GAG-antigener blandt GAG-polyproteinet eller matrixproteinet eller capsidproteinet eller nukleocapsidproteinet eller er et fragment af et sådant polyprotein eller af et sådant matrix-, capsid eller nukleocapsidproteinet eller er et GAG-antigen, der er modificeret i forhold til det naturlige GAG-antigen, især ved mutation, herunder ved deletion, substitution eller tilføjelse af en eller adskillige aminosyrerester i aminosyresekvensen, eller er modificeret ved posttranslationelle modifikationer, hvor det modificerede GAG-antigen er valgt, så det enten er biologisk funktionelt eller biologisk ikke-funktionelt.
20. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 17, hvor det rekombinante polynukleotid koder for et biologisk ikke-funktionelt polypeptid, der er afledt af et GAG-antigen fra HIV eller fra SIV eller fra FIV, hvor polypeptidet ikke åbner mulighed for dannelsen af GAG-pseudopartikler eller GAG-POL-pseudopartikler fra celler, der er transduceret med de lentivirale vektorer.
21. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 20, hvor det GAG-afledte antigen er et GAGAmyr-protein, der er fri for myristylering.
22. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 18, hvor det GAG-afledte antigen har aminosyresekvensen i figur 21,26 eller 38.
23. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 19, hvor polynukleotidet, der koder for GAG-polyproteinet eller et polypeptid, der er afledt deraf, udtrykkes af en kodonoptimeret nukleotidsekvens til muliggørelse af forbedret translation i mammaliaceller, især i humane celler, i forhold til nukleotidsekvensen for det native gen.
24. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 20, hvor det rekombinante polynukleotid yderligere koder for et polypeptid valgt blandt polypeptider afledt af et NEF-antigen, et TAT-antigen, et REV-antigen fra et immundefektvirus, et POL-antigen fra et immundefektvirus eller en kombination deraf.
25. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 20, hvor det rekombinante polynukleotid koder for et fusionsprotein, der omfatter det GAG-afledte antigen med sekvensen i figur 21, det POL-afledte antigen, der omfatter eller har aminosyresekvensen i figur 21, og det NEF-afledte antigen, der omfatter eller har aminosyresekvensen, der fremgår af figur 21, hvor fusionsproteinet har en af følgende strukturer: 5'-GAG-POL-NEF-3' eller 5'-POL-NEF-GAG-3' eller 5'-POL-GAG-NEF-3' eller 5'-NEF-GAG-POL-3' eller 5'-NEF-POL-GAG-3' eller 5'-GAG-NEF-POL-3'.
26. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 25, hvor de lentivirale vektorer (i) og/eller (ii) er formuleret i en sammensætning, der er fri for et adjuvans for immunresponset.
27. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 26, som yderligere omfatter et immunmodulerende middel.
28. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 27, hvor de lentivirale vektorer er formuleret i sammensætninger, der er egnet til injektion til en vært.
29. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 27, hvor de lentivirale vektorer er formuleret i sammensætninger, der er egnet til subkutan injektion.
30. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 29 til anvendelse i et administrationsprogram, der omfatter priming af immunresponset og efterfølgende boosting af immunresponset i en mammaliavært, hvor den (i) lentivirale vektor, der er pseudotypet med det første VSV-G-protein, administreres adskilt i tid fra den (ii) lentivirale vektor, der er pseudotypet med det andet VSV-G-protein, og hvis de er til stede, de (iii) lentivirale vektorer, der er pseudotypet med det tredje VSV-G-protein, hvor hver af de lentivirale vektorer (i) og (ii) og, hvis de er til stede, (iii) administreres enten til priming eller til boosting af immunresponset.
31. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 5 til 30, hvor den lentivirale vektor, der er pseudotypet med VSV-G-proteinet fra Indiana-stammen, anvendes til priming, og den lentivirale vektor, der er pseudotypet med VSV-G-proteinet fra New Jersey-stammen, anvendes til boosting, eller hvor den lentivirale vektor, der er pseudotypet med VSV-G-proteinet fra New jersey-stammen, anvendes til priming, og den lentivirale vektor, der er pseudotypet med VSV-G-proteinet fra Indiana-stammen, anvendes til boosting.
32. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 26 til terapeutisk behandling af humane værter, der er inficeret med et humant immundefektvirus (HIV).
33. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 26 til terapeutisk behandling af humane værter, der er inficeret med HIV-1 eller HIV-2.
34. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 31 til profylaktisk behandling af humane værter mod infektion af et humant immundefektvirus.
35. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 30 til profylaktisk behandling af humane værter mod infektion af HIV-1 eller HIV-2.
36. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 35 til anvendelse i et terapeutisk program, der også omfatter administration af et eller flere antiretrovirale kemiske lægemidler, der forhindrer retrovirusreplikation.
37. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 35 til anvendelse i et terapeutisk program, der også omfatter administration af et eller flere anti retrovi rale kemiske lægemidler, der forhindrer retrovirusreplikation, valgt blandt inhibitor(er) af retroviral reverse transkriptase (RT) og inhibitor(er) af retroviral protease.
38. Kombination af forbindelser til anvendelse ifølge krav 37, hvor en eller adskillige inhibitorer af retroviral reverse transkriptase og en eller adskillige inhibitorer af retroviral protease anvendes til administration.
39. Kombination af forbindelser til anvendelse ifølge krav 37 eller 38 til anvendelse samtidig med anti retrovi rale lægemidler.
40. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 33 til 36, hvor administrationen af forbindelserne varer ved, efter at administrationen af det eller de anti retrovi rale lægemidler er standset, eller hvor administrationen af anti retrovi rale lægemidler afbrydes adskillige gange i et bestemt tidsrum under administration af forbindelserne.
41. Kombination af forbindelser til anvendelse ifølge et hvilket som helst af kravene 1 til 39 i et administrationsprogram, der omfatter priming af immunresponset og efterfølgende boosting af immunresponset hos en mammaliavært, - til kontrol af viræmien efter eksponering for eller efter infektion med retrovirus, særligt et HIV, og især til begrænsning eller reducering af virusbelastningen hos værten; og/eller - til induktion af beskyttende cellulær immunitet mod retrovi russet, især HIV, hos en vært; og/eller - til beskyttelse mod virusreplikation efter eksponering for eller efter infektion med HIV-retrovirusset; og/eller - til beskyttelse mod udtømning af det centrale hukommelses-CD4+-T-cellerespons, især i den akutte fase af infektion med retrovi russet, især HIV; og/eller - til bevarelse af det centrale hukommelses-CD4+-T-cellerespons, især i den kroniske fase af infektion med retrovi russet, især HIV; og/eller - til tidligere og/eller højere tilbagevenden af det na'ive og centrale hukommelses-CD8+-T-cellerespons under primær infektion med retrovi russet, især HIV; og/eller - til forebyggelse mod viral undvigelse fra immunpres til derved muliggørelse af langtidskontrol af infektionen med retrovi russet, især HIV.
DK08827144.0T 2007-08-03 2008-08-01 Lentivirale genoverførselsvektorer og deres medicinske anvendelser DK2185192T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07290980.7A EP2020444B1 (en) 2007-08-03 2007-08-03 Defective non-integrative lentiviral transfer vectors for vaccines
EP07290979 2007-08-03
EP07291251.2A EP2047861B1 (en) 2007-10-12 2007-10-12 Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
EP08156405 2008-05-16
PCT/IB2008/002930 WO2009019612A2 (en) 2007-08-03 2008-08-01 Lentiviral gene transfer vectors and their medicinal applications

Publications (1)

Publication Number Publication Date
DK2185192T3 true DK2185192T3 (da) 2019-02-18

Family

ID=40341833

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08827144.0T DK2185192T3 (da) 2007-08-03 2008-08-01 Lentivirale genoverførselsvektorer og deres medicinske anvendelser

Country Status (14)

Country Link
US (3) US8420104B2 (da)
EP (1) EP2185192B1 (da)
JP (3) JP5773648B2 (da)
CN (2) CN108114276A (da)
AU (1) AU2008285224B2 (da)
BR (1) BRPI0813194B8 (da)
CA (1) CA2695433C (da)
DK (1) DK2185192T3 (da)
ES (1) ES2708856T3 (da)
HK (1) HK1252608A1 (da)
IL (1) IL243569A (da)
MX (2) MX2010001379A (da)
PT (1) PT2185192T (da)
WO (1) WO2009019612A2 (da)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
BRPI0813194B8 (pt) 2007-08-03 2021-05-25 Centre Nat Rech Scient kit, partículas de vetor lentiviral, composição de vetores plasmídicos, antígeno derivado de hiv-1 quimérico, proteína de envelope de vsv-g, moléculas de ácido nucleico, composição imunogênica e uso de um vetor lentiviral
WO2010129602A2 (en) * 2009-05-04 2010-11-11 Fred Hutchinson Cancer Research Center Cocal vesiculovirus envelope pseudotyped retroviral vectors
EP2366776A1 (en) * 2010-03-01 2011-09-21 Epixis A method for measuring viral infectivity
DK2385107T3 (da) * 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vektor-baserede immunologiske forbindelser mod malaria
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
WO2011147622A1 (en) 2010-05-26 2011-12-01 Deutsches Rheuma-Forschungszentrum Berlin Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells
CN102277380B (zh) * 2010-06-08 2013-03-27 齐鲁制药有限公司 一种dhfr互补表达的共转染真核表达载体及其制备方法与应用
CN103003825A (zh) 2010-06-25 2013-03-27 奥马尔科网络解决方案有限公司 用于柔性基板的安全性改进
WO2012069657A1 (en) 2010-11-26 2012-05-31 Institut Pasteur Identification of a human gyrovirus and applications.
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013140169A1 (en) * 2012-03-20 2013-09-26 Isis Innovation Limited Immunogenic composition and methods of use thereof
JP2015512263A (ja) 2012-03-30 2015-04-27 イミューン デザイン コーポレイション Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
CA2932542C (en) 2012-12-14 2023-06-06 The Regents Of The University Of California Viral vector nanocapsule for targeting gene therapy and its preparation
AU2014277092B2 (en) 2013-06-03 2019-04-04 Theravectys Lentiviral vectors containing an MHC class I, MHC class II, or beta-2 microglobulin upstream promoter sequence
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
EP3009144A1 (en) * 2014-10-15 2016-04-20 Theravectys Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
WO2015063707A1 (en) * 2013-10-31 2015-05-07 Theravectys LENTIVIRAL VECTORS FOR INDUCING CD4+ and CD8+ IMMUNE RESPONSES IN VACCINATION OF HUMANS
EP2878674A1 (en) * 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
EP2878667A1 (en) 2013-11-29 2015-06-03 Institut Pasteur TAL effector means useful for partial or full deletion of DNA tandem repeats
SG11201606148UA (en) * 2014-01-27 2016-08-30 Theravectys Lentiviral vectors for generating immune responses against human t lymphotrophic virus type 1
KR102416194B1 (ko) * 2014-03-01 2022-07-04 프로펙츄스 바이오사이언스, 인크. 재조합 이스파한 바이러스 벡터
WO2016037161A2 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
EP3211003A1 (en) 2016-02-24 2017-08-30 Institut Pasteur T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3235828A1 (en) 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
WO2017194902A2 (fr) * 2016-05-13 2017-11-16 Vectalys Particule pour l'encapsidation d'un système d'ingénierie du génome
CN106399376A (zh) * 2016-08-31 2017-02-15 河南省华隆生物技术有限公司 一种整合缺陷型慢病毒载体、其制备方法及应用
MX2019008143A (es) 2017-01-07 2020-01-13 Selecta Biosciences Inc Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos.
WO2018140946A1 (en) 2017-01-30 2018-08-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
JP7341900B2 (ja) 2017-03-03 2023-09-11 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のためのｃｄ１９組成物及び方法
AU2018226857B2 (en) 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
FR3065967B1 (fr) * 2017-05-05 2022-06-03 Univ Paris Descartes Procede in vitro de detection et de quantification de l'adn du vih-2
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
PL3684786T3 (pl) * 2017-09-22 2024-12-16 Centre National De La Recherche Scientifique (Cnrs) Zmutowana glikoproteina wirusa pęcherzykowego zapalenia jamy ustnej
JP2020535160A (ja) * 2017-09-28 2020-12-03 タンデム カンパニー，リミテッド 癌治療用の新規な組換え原形質膜をベースとする小胞体
JP6994714B2 (ja) 2017-10-03 2022-01-14 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
CN111225682A (zh) * 2017-10-20 2020-06-02 吉尼松公司 合胞素用于将药物和基因靶向递送至肺组织的用途
BR112020009157A2 (pt) 2017-11-09 2020-10-27 Institut Pasteur poliepítopo quimérico, polinucleotídeo, vetor, célula hospedeira e composição imunogênica
US12178908B2 (en) 2018-02-26 2024-12-31 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
JP6917942B2 (ja) 2018-04-11 2021-08-11 株式会社日立製作所 データ分析サーバ、データ分析システム、及びデータ分析方法
CN110577585A (zh) * 2018-06-07 2019-12-17 中国医学科学院基础医学研究所 水泡型口炎病毒包膜糖蛋白变体及其构建方法和应用
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN113631703B (zh) * 2018-12-04 2025-03-25 瑞威帝基因传递股份有限公司 使用泊洛沙胺的病毒传导
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020223205A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2020243261A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
EP3770264A1 (en) 2019-07-22 2021-01-27 Genethon Precise integration using nuclease targeted idlv
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
JP2023516789A (ja) * 2020-03-09 2023-04-20 ヤンセン バイオテツク，インコーポレーテツド 組換えベクター核酸の統合を定量化するための組成物及び方法
CN111593073B (zh) * 2020-03-18 2022-03-08 睿丰康生物医药科技(浙江)有限公司 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒
WO2021188996A1 (en) * 2020-03-20 2021-09-23 The Broad Institute, Inc. Compositions and methods for enhanced lentiviral production
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
WO2022051240A1 (en) * 2020-09-01 2022-03-10 The Trustees Of The University Of Pennsylvania Improved generation of lentiviral vectors for t cell transduction using cocal envelope
KR102379144B1 (ko) * 2020-09-29 2022-03-28 한국표준과학연구원 SARS-CoV-2의 RNA 표준물질 및 이를 이용한 코로나19바이러스(SARS-CoV-2) 감염 진단 정보의 제공방법
KR102283733B1 (ko) * 2020-12-22 2021-08-02 한국표준과학연구원 ＣＯＶＩＤ-19 바이러스 진단을 위한, ＳＡＲＳ-ＣｏＶ-2 포장 ＲＮＡ 표준물질, 이의 제조방법 및 이의 용도
US20240084330A1 (en) * 2021-01-28 2024-03-14 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用
CN115247190B (zh) * 2021-04-28 2024-06-18 沛尔生技医药股份有限公司 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用
TWI758171B (zh) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
US20240316102A1 (en) 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
KR20240073006A (ko) 2021-08-11 2024-05-24 사나 바이오테크놀로지, 인크. 동종이계 세포 요법을 위한 유전자 변형된 1차 세포
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
EP4433081A1 (en) * 2021-11-15 2024-09-25 Theravectys Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
WO2023114918A1 (en) 2021-12-16 2023-06-22 Ludwig Institute For Cancer Research Ltd Antisense transfer vectors and methods of use thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4473097A1 (en) 2022-02-02 2024-12-11 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
AU2023316754A1 (en) * 2022-07-27 2025-02-13 Institut Pasteur Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
CN116024269B (zh) * 2022-11-18 2024-02-02 复百澳(苏州)生物医药科技有限公司 一种冠状病毒假病毒颗粒的制备方法
WO2024129696A1 (en) 2022-12-12 2024-06-20 Retromer Therapeutics Corp. Aav and lentiviral constructs comprising a sorl1 mini-gene for use in treating neurodegenerative diseases
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024149284A1 (en) * 2023-01-10 2024-07-18 Nanjing Legend Biotech Co., Ltd. Regulatory sequences and uses thereof
WO2024178386A1 (en) 2023-02-24 2024-08-29 Aarhus Universitet Methods of treating endosomal trafficking diseases
WO2024213153A1 (zh) * 2023-04-13 2024-10-17 深圳市济因生物科技有限公司 一种载体及其应用
US20240390474A1 (en) * 2023-04-27 2024-11-28 Genvivo, Inc. Compositions and methods for therapeutic or vaccine delivery
EP4704867A1 (en) 2023-05-03 2026-03-11 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer
CN119639818A (zh) * 2025-02-18 2025-03-18 南京市计量监督检测院 一种假病毒颗粒的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941703D1 (de) * 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
KR100807016B1 (ko) * 2000-06-01 2008-02-25 가부시키가이샤 디나벡크 겐큐쇼 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터
EP1320621A4 (en) 2000-09-15 2005-11-23 Merck & Co Inc IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02)
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
SK287471B6 (sk) 2001-05-03 2010-11-08 Fit Biotech Oyj Plc Expresné vektory a ich použitie
CN100557023C (zh) 2001-06-08 2009-11-04 株式会社载体研究所 利用vsv-g假型化猴免疫缺陷病毒载体将基因导入灵长类胚胎干细胞
CN1606625A (zh) 2001-10-31 2005-04-13 南非医学研究会 Hiv－1亚型分离株调节/附加基因及其修饰物和衍生物
US20060257416A1 (en) * 2003-06-13 2006-11-16 Palmowski J M Materials and methods for improved vaccination
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory IMPROVED MVA VACCINES
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
KR101253363B1 (ko) * 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 개선된 아데노바이러스 벡터 및 그것의 용도
WO2006127585A2 (en) * 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
EP1885186B1 (en) * 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
ZA200803883B (en) 2005-11-08 2009-07-29 South African Medical Research Council Chimaeric HIV-1 subtype C Gag-virus-like particles
EP1968629A2 (en) 2005-12-21 2008-09-17 Glaxo Group Limited Method of eliciting immune response
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
WO2007091066A1 (en) 2006-02-07 2007-08-16 Ucl Business Plc Applications of non-integrating lentiviral vectors
BRPI0813194B8 (pt) 2007-08-03 2021-05-25 Centre Nat Rech Scient kit, partículas de vetor lentiviral, composição de vetores plasmídicos, antígeno derivado de hiv-1 quimérico, proteína de envelope de vsv-g, moléculas de ácido nucleico, composição imunogênica e uso de um vetor lentiviral

Also Published As

Publication number Publication date
CA2695433A1 (en) 2009-02-12
JP5773648B2 (ja) 2015-09-02
JP2018076363A (ja) 2018-05-17
CA2695433C (en) 2025-05-06
US9328146B2 (en) 2016-05-03
BRPI0813194B8 (pt) 2021-05-25
US20100297168A1 (en) 2010-11-25
JP2010535495A (ja) 2010-11-25
BRPI0813194B1 (pt) 2020-05-05
CN108114276A (zh) 2018-06-05
PT2185192T (pt) 2019-02-12
MX342449B (es) 2016-09-29
CN102083462B (zh) 2015-02-18
JP2015062425A (ja) 2015-04-09
ES2708856T3 (es) 2019-04-11
IL243569A (en) 2016-07-31
US20120315296A1 (en) 2012-12-13
BRPI0813194A2 (pt) 2016-11-01
US8709799B2 (en) 2014-04-29
MX2010001379A (es) 2010-06-08
HK1252608A1 (zh) 2019-05-31
EP2185192A2 (en) 2010-05-19
EP2185192B1 (en) 2018-10-31
JP6480028B2 (ja) 2019-03-06
WO2009019612A2 (en) 2009-02-12
US8420104B2 (en) 2013-04-16
WO2009019612A3 (en) 2009-12-23
AU2008285224A1 (en) 2009-02-12
US20140248306A1 (en) 2014-09-04
AU2008285224B2 (en) 2015-01-22
CN102083462A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
DK2185192T3 (da) Lentivirale genoverførselsvektorer og deres medicinske anvendelser
CN103314104B (zh) 基于慢病毒载体的抗疟疾免疫化合物
CN1852734B (zh) 共有/祖先免疫原
EP2047861B1 (en) Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
DK2020444T3 (da) Defekte ikke-integrative lentivirale over-førselsvektorer til vacciner
AU2013203404B2 (en) Lentiviral gene transfer vectors and their medicinal applications
CN104169295B (zh) 突变的慢病毒env蛋白及其用作药物的用途
HK1140678B (en) Lentiviral gene transfer vectors and their medicinal applications
HK1140678A (en) Lentiviral gene transfer vectors and their medicinal applications
HK1126146A (en) Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
Gallinaro Integrase defective lentiviral vector as a vaccine platform for delivering HIV-1 antigens
TW202423456A (zh) 表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
Langhammer Neutralisierende Antikörper gegen die transmembranen Hüllproteine von Retroviren
McKenna Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins
MXPA06003076A (en) Consensus/ancestral immunogens